SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

Initial investment in REMS means big pay-put for pharma, says RAPS author

By Natalie Morrison , 06-Jun-2012
Last updated on 06-Jun-2012 at 13:05 GMT

REMS for drugmakers: Invest early for big pay-out, says expert
REMS for drugmakers: Invest early for big pay-out, says expert
Loading...

A bigger initial pay-out for REMS means long-term profitability for drugsmakers, says Quintiles Ed Tabor.

Tabor’s book, ‘Risk Evaluation and Mitigation Strategies for US Drug Development’, was recently launched with RAPS (Regulatory Affairs Professionals Society).

In it, he describes the REMS (risk evaluation and mitigation strategies) programme and how companies can dodge the hurdles of the application process, which has been in place since the US FDA (Food and Drug Administration) brought the strategy into play in 2007.

Speaking to in-PharmaTechnologist.com, Tabor told us that though some companies are still concerned about additional costs and delays of implementing the program the benefits outweigh the risks.

“One can view the REMS as a continuum of requirements ranging from informational such as medical guides or plans, implementation plans, and elements to ensure safe use abbreviated (ETASU) at the other end of the spectrum,” he said.

“The existence of REMS has in some cases allowed the drugs to be approved, the thinking being that the REMS provide the additional controls that prevent some of the risks that would be there without the controls.”

He added that though preparing REMS does cost money, the programme often speeds drugs to market, which means an extra year of sales at the time of peak revenue.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE
Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

ASI has teamed up with Chromatan in order to deliver single-use and column-free capture...

Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests

John Giannone - incoming IPEC-Americas chairman

Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

Special Report from ATMI's Belgian Facility

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

Walter Dissinger

President , BASF nutrition and health

Optimism is returning to the pharma fine chemicals sector, says analyst

Optimism is returning to the pharma fine chemicals sector, says analyst

Jan Ramakers

Industry consultant, Jan Ramakers Fine Chemical Consulting Group

Capsugel expands liquid fill capsule capabilities

Keith Hutchison,

Senior VP of research and development (R&D) , Capsugel

New filtration tech boosts biomanufacturing yields, says Sartorius

New filtration tech boosts biomanufacturing yields, says Sartorius

Jens Meyer

Product manager for filtration technologies, Sartorius Stedim

Submit good REMS proposals for FDA brownie points, says RAPS author

Submit good REMS proposals for FDA brownie points, says RAPS author

Ed Tabor

VP of strategic drug development , Quintiles

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Missy Lowery

Marketing Manager for the Americas, Capsugel

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Cory Stevenson & Brandon Pence

Thermo Fisher Scientific

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

Eric Isberg

Global Product Manager, ATMI

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Key Industry Events

 

Access all events listing

Our events, Events from partners...